Table 11. mRNA Vaccines in Phase 2 or More Advanced Clinical Trials for Cancersa.
Vaccine name | CAS Registry Number | Disease indication | Antigen | Company |
---|---|---|---|---|
Autogene cevumeran | 2365453-34-3 | Melanoma; colorectal cancer | Patient-specific neoantigens | BioNTech |
mRNA 4157 | 2741858-84-2 | Melanoma | Up to 34 neoantigens | Moderna |
mRNA 4359 | 2900354-08-5 | Melanoma; non-small-cell lung carcinoma | IDO and PD-L1 | Moderna |
BNT 111 | 2755828-88-5 | Melanoma | Mix of four melanoma-associated antigens | BioNTech |
BNT 112 | 2900354-09-6 | Prostate cancer | Mix of five prostate cancer-specific antigens | BioNTech |
BNT 113 | 2882951-85-9 | PV16+ head-and-neck squamous carcinoma | HPV16-derived tumor antigens (oncoprotein E6 and E7) | BioNTech |
CV 9202 | 1665299-76-2 | Non-small-cell lung cancer | NY-ESO-1, MAGE C1, MAGE C2, TPBG (5T4), survivin, MUC1 | CureVac |
CV 9103 | 2882951-83-7 | Prostate cancer | Mix of four prostate cancer-associated antigens | CureVac |
SW 1115C3 | 2882951-82-6 | Non-small-cell lung cancer; esophageal cancer | Patient-specific neoantigens | Stemirna Therapeutics |
Rocapuldencel T; AGS 003 | 2396421-01-3 | Non-small-cell lung cancer; lung cancer; bladder and renal cancer | Autologous tumor antigen and CD40L-loaded dendritic cell immunotherapy | Argos Therapeutics |
Data from the CAS Content Collection, Clinicaltrials.gov, and Pharmaprojects.